Right Care Action Week: October 15-21

The Lown Institute’s Right Care Alliance (RCA) is revving up across the country for Right Care Action Week (October 15-21). For the third consecutive year, healthcare practitioners and ‘consumers’ alike will ask people ‘What worries you most about healthcare?’ — with this year’s focus being on what drives up health care costs.

Some cost pushers . . . → Read More: Right Care Action Week: October 15-21

Book Review: The Thinking Woman's Guide to Breast Cancer by Janet Maker

The Thinking Woman’s Guide to Breast Cancer is a concise and well-written gift for women navigating the medical system and trying to make better-informed decisions. Based on her personal experience with breast cancer and well-honed investigative and critical thinking skills, Janet Maker Ph.D. offers readers a full spectrum of insights, resources, and even warnings when . . . → Read More: Book Review: The Thinking Woman’s Guide to Breast Cancer by Janet Maker

Update on Lown Institute's Right Care Action Week

The Lown Institute’s Right Care Alliance is building a grassroots social movement to fix healthcare by reaching out to the public and healthcare practitioners. The mission is basic and profound:

Profit-driven overuse, under-use, and misuse of medical tests and treatments have subverted the work of health care providers. A much better health care system is . . . → Read More: Update on Lown Institute’s Right Care Action Week

Inaccurate Claims about the Unequivocal Benefit of Early Detection Persist Despite Evidence to the Contrary.

When Dr. Susan Love was updating the 2015 edition of her Breast Book for a chapter titled, “When Cancer Comes Back,” she asked women with metastatic (stage IV) breast cancer what they wished the public knew about this disease. Many replied that, “the ‘early detection’ of an invasive cancer through [mammography] screening does not guarantee . . . → Read More: Inaccurate Claims about the Unequivocal Benefit of Early Detection Persist Despite Evidence to the Contrary.

What We Can Learn from New ACS Guidelines on Screening Mammography

Since 2003 the American Cancer Society (ACS) has told women repeatedly to get screened with mammograms every year starting at age 40, or younger if they are at higher risk. The society also recommended clinical breast exams (CBEs) each year for women over age 40 and periodically for women younger than that. During this year’s . . . → Read More: What We Can Learn from New ACS Guidelines on Screening Mammography

Research Brief: Breast Cancer Mortality After a Diagnosis of DCIS

A recent study by Dr. Steven A. Narod and colleagues provides evidence that for most women diagnosed with ductal carcinoma in situ, DCIS, the condition will not impact life expectancy. It supports a mounting call for research to determine which cases of DCIS would benefit from milder interventions or preventive strategies rather than more aggressive . . . → Read More: Research Brief: Breast Cancer Mortality After a Diagnosis of DCIS

Surge in competition in genetic risk screening warrants caution

A recent article in The New York Times “New Genetic Tests for Breast Cancer Hold Promise” describes new and cheaper tests for BRCA1 and 2 gene mutations that carry added risk for breast and ovarian cancers. Medical guidelines generally limit testing of the so-called “breast cancer genes” to the small percentage of people who already . . . → Read More: Surge in competition in genetic risk screening warrants caution

Tamoxifen for Prevention of Breast Cancer: Extended Long-Term Follow-Up of the IBIS-I Breast Cancer Prevention Trial

The longest randomized controlled trial to date on breast cancer chemoprevention with tamoxifen (a synthetic drug that blocks the effects of estrogen), IBIS-I, recently reported, after 16 years of follow-up, a 29 percent reduction in breast cancer (invasive and noninvasive types) for ‘high-risk’ women taking the drug for 5 years. The reduction in breast cancer . . . → Read More: Tamoxifen for Prevention of Breast Cancer: Extended Long-Term Follow-Up of the IBIS-I Breast Cancer Prevention Trial

Book Review and Analysis -- From Zero to Mastectomy: What I Learned and You Need to Know About Stage 0 Breast Cancer

At age 52, Jackie Fox was diagnosed with DCIS, ductal carcinoma in situ, a form of breast cancer labeled stage zero, compared to stages 1 to 4. This slim book is an up-close and personal story of Fox’s roller coaster journey — from the moment her doctor gave her the diagnosis, telling her it was . . . → Read More: Book Review and Analysis — From Zero to Mastectomy: What I Learned and You Need to Know About Stage 0 Breast Cancer